Wegovy
Payments companies reported to CMS as associated with Wegovy. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Wegovy, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Wegovy
These are the largest totals companies reported as associated with Wegovy. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Tiffany Lowe Clayton | Fuquay Varina, NC | Obesity Medicine (Family Medicine) | $174,175.16 |
| Amira Ayad | Bakersfield, CA | Family Medicine | $164,404.88 |
| Ethan Lazarus | Denver, CO | Family Medicine | $164,330.39 |
| Jeffrey Sicat | Glen Allen, VA | Endocrinology, Diabetes & Metabolism | $159,154.68 |
| Ken Fujioka | San Diego, CA | Endocrinology, Diabetes & Metabolism | $156,750.29 |
| Dana Portenier | Durham, NC | Surgery | $151,039.78 |
| Holly Lofton | New York, NY | Obesity Medicine (Preventive Medicine) | $149,436.88 |
| Dana Trippi | Las Vegas, NV | Emergency Medicine | $147,970.99 |
| Michael Kaplan | Smithtown, NY | Internal Medicine | $147,219.45 |
| Lawrence Herman | Holbrook, NY | Physician Assistant | $143,707.98 |
Prescribed Wegovy?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.